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ABSTRACT Ischemic stroke (IS) is among the leading causes of death in Western countries. There is a signiﬁcant
genetic component to IS susceptibility, especially among young adults. To date, research to identify genetic loci
predisposing to stroke has met only with limited success. We performed a genome-wide association (GWA) analysis
of early-onset IS to identify potential stroke susceptibility loci. The GWA analysis was conducted by genotyping 1
million SNPs in a biracial population of 889 IS cases and 927 controls, ages 15–49 years. Genotypes were imputed
using the HapMap3 reference panel to provide 1.4 million SNPs for analysis. Logistic regression models adjusting for
age, recruitment stages, and population structure were used to determine the association of IS with individual SNPs.
Although no single SNP reached genome-wide signiﬁcance (P , 5 · 1028), we identiﬁed two SNPs in chromosome
2q23.3, rs2304556 (in FMNL2; P ¼ 1.2 · 1027) and rs1986743 (in ARL6IP6; P ¼ 2.7 · 1027), strongly associated with
early-onset stroke. These data suggest that a novel locus on human chromosome 2q23.3 may be associated with IS
susceptibility among young adults.
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Age-related stroke is a common debilitating disease that ranks among
the leading causes of death in the United States (Rosamond et al.
2008). Ischemic stroke (IS) comprises approximately 85% of all
strokes. While hypertension, cigarette smoking, and diabetes are
well-established risk factors for IS, family and twin studies provide
evidence that IS aggregates within families (Flossmann et al. 2004),
thus implicating a genetic contribution to stroke susceptibility.
Efforts to identify the genetic determinants of IS have had limited
success. One strategy to enhance the chances of identifying stroke
susceptibility genes is to study stroke cases that are more likely to have
a strong genetic predisposition. Such cases might include those with
a strong family history of stroke or those experiencing a stroke at
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Volume 1 | November 2011 | 505a relatively young age. Such strategies have been successful in
identifying genes associated with early-onset forms of other complex
diseases, including breast cancer (Walsh et al. 2006), Parkinson’sd i s -
ease (Lesage et al. 2008), obesity (Hinney et al. 2007; Scherag et al.
2010), inﬂammatory bowel disease (Imielinski et al. 2009), and myo-
cardial infarction (Kathiresan et al. 2009). Evidence from twin (Brass
et al. 1992; Brass et al. 1998; Hassan and Markus 2000) and familial
aggregation studies (Schulz et al. 2004), in fact, supports a stronger
genetic contribution to early-onset than later-onset stroke. We have
previously reported in our own study of young-onset stroke that the
proportion of cases reporting a family history of stroke increases with
decreasing age of the proband (MacClellan et al. 2006).
We have performed a case-control study of IS in subjects ages
15–49 years. In this report, we present results of a genome-wide
association (GWA) analysis based on 1.4 million SNPs genotyped
and/or imputed across the genome for their association with risk of IS.
MATERIALS AND METHODS
Study population
The Genetics of Early Onset Stroke (GEOS) Study is a population-
based, case-control study designed to identify genes associated with
early-onset ischemic stroke and to characterize interactions of
identiﬁed stroke genes and/or SNPs with environmental risk factors.
Participants were recruited from the greater Baltimore-Washington
area in four different periods: Stroke Prevention in Young Women-1
(SPYW-1) conducted from 1992 to 1996, Stroke Prevention in Young
Women-2 (SPYW-2) conducted from 2001 to 2003, Stroke Prevention
in Young Men (SPYM) conducted from 2003 to 2007, and Stroke
Prevention in Young Adults (SPYA) conducted in 2008. From these
samples, we identiﬁed a total of 921 cases and 941 controls that
consented to having their DNA used for genetic studies of stroke. This
study was conducted with the consent of all study participants and
was approved by the University of Maryland at Baltimore Institutional
Review Board.
Deﬁnitions of cases and controls
“Case participants” were hospitalized with a ﬁrst cerebral infarction
identiﬁed by discharge surveillance from one of the 59 hospitals in the
greater Baltimore-Washington area and direct referral from regional
neurologists. IS with the following characteristics were excluded from
participation: stroke occurring as an immediate consequence of
trauma; stroke within 48 hr after a hospital procedure, stroke within
60 days after the onset of a nontraumatic subarachnoid hemorrhage,
and cerebral venous thrombosis. Additional exclusions for these ge-
netic analyses are listed in Table 1. All cases had neuroimaging that
was consistent with cerebral infarction, although neuroimaging was
not used for case ascertainment. The abstracted hospital records of
cases were reviewed and adjudicated for IS subtype by a pair of
neurologists according to previously published procedures (Johnson
et al. 1995; Kittner et al. 1998), with disagreements resolved by a third
neurologist. The IS subtype classiﬁcation system retains information
on all probable and possible causes, and it is reducible to the more
widely used TOAST system (Adams et al. 1993) that assigns each case
to a single category. All cases had age of ﬁrst stroke between 15 and 49
years and were recruited within three years of stroke.
“Control participants” without a history of stroke were identiﬁed
by random-digit dialing. Controls were balanced to cases by age and
region of residence in each study and were additionally balanced for
race in SPYW-2 and SPYM. Traditional stroke risk factors and other
study variables, including age, race/ethnicity, history of hypertension,
diabetes, myocardial infarction (MI), and current smoking status (de-
ﬁned as use within one month prior to event for cases and at a com-
parable reference time for controls), were also collected during
a standardized interview.
Genotyping
Genomic DNA was isolated from a variety of sample types, including
cell line (55.2%), whole blood (43.1%), mouth wash (0.4%), and buccal
swab (0.05%). Whole-genome ampliﬁcation (Qiagen REPLI-g kit,
Valencia, CA) was used to obtain sufﬁcient DNA for genotyping in
1.3% of samples. The distribution of sample types did not differ
signiﬁcantly between cases and controls (56.3% cell lines in cases vs.
54.1% in controls; 41.5% whole blood in cases vs. 44.9% in controls).
Samples were genotyped at the Johns Hopkins Center for Inherited
Disease Research (CIDR), and genotyping was performed using the
Illumina HumanOmni1-Quad_v1-0_B BeadChip (Illumina, San
Diego, CA). Case and control samples were balanced across the plates,
and self-identiﬁed whites and African Americans were placed on
different plates. Samples of 50 self-reported whites were also placed
on African American plates for quality control. All study samples,
including 39 blind duplicates (19 whites and 20 African Americans),
were plated and genotyped together with 42 HapMap control samples,
including 26 Utah residents with ancestry from northern and Western
Europe (CEU) and 16 Yoruba (YRI) samples, and all samples were
processed together in the lab. Allele cluster deﬁnitions for each SNP
were determined using Illumina BeadStudio Genotyping Module ver-
sion 3.3.7, Gentrain version 1.0, and the combined intensity data from
all released samples. Genotypes were not called if the quality threshold
(Gencall score) was below 0.15.
Genotypes of a total of 1827 study individuals (99% of attempted
samples) were released by CIDR, and all had a genotype call rate
greater than 98%. Genotyping concordance rate was 99.996% based
on study duplicates. We excluded 11 individuals from analysis due to
unexpected duplicates, gender discrepancy, or unexpected relatedness,
leaving a total of 1816 individuals (889 cases and 927 controls) in the
ﬁnal analysis. A total of 1,014,719 SNPs were released by CIDR
(99.83% of attempted). Genotypes were not released for SNPs that had
call rates less than 85%, a cluster separation value of less than 0.2,
more than 1 HapMap replicate error, more than a 5% (autosomal) or
6% (X) difference in call rate between sexes, more than 0.3% male AB
frequency (X), or more than a 11.3% (autosomal) or 10% (XY)
difference in AB frequency. Individual SNPs were excluded post-
analysis if they had excessive deviation from Hardy-Weinberg
equilibrium (HWE) proportions (P , 1.0 · 1027) or genotype call
rates less than 95%. Departure from HWE was assessed by x2 test
among controls only and among each ethnic group separately. For this
report, only SNPs having minor allele frequencies (MAF) greater than
1% and SNPs passing HWE ﬁltering in both genetically deﬁned (see
Statistical Analysis below) European ancestry (EA) and African an-
cestry (AA) populations were included (N ¼ 784,766 SNPs).
Imputation
Imputation was performed for genetically deﬁned EA cohort (N ¼
946) and AA cohort (N ¼ 733) separately using BEAGLE v3.3 soft-
ware (Browning and Browning 2009). Genetically deﬁned EA partic-
ipants were those within two standard deviations (SD) of the mean of
the ﬁrst and second principal components for subjects self-identiﬁed
as “white,” and similarly, genetically deﬁned AA participants were
those within two SD of the mean of the ﬁrst and second principal
components for those self-identiﬁed as “African American.” The
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HapMap Phase 3 populations were used as the reference panel for EA
cohort imputation. A combination of ﬁve HapMap Phase 3 popula-
tions, CEU, TSI, YRI, Luhya in Webuye, Kenya (LWK), and African
ancestry in southwest United States (ASW), was used as reference
panel for AA cohort imputation, in accordance with the recommen-
dation that a mixture of populations be used as the reference panel for
African Americans (Hao et al. 2009). All SNPs failing the composite
quality ﬁlter were removed [i.e. SNPs with missing call rate $ 5%,
SNPs with Mendelian errors in three HapMap trios . 0, HWE P , 1
· 1024, and SNPs with more than one discordant genotype call across
the 89 duplicated study samples (39 blind duplicates and 50 white
duplicates plated on African American plates]. All remaining SNPs
having a MAF $ 1% in each respective cohort were used as input
SNPs for imputation. A total of 1,387,466 SNPs were obtained via
imputation, which included 532,595 and 582,186 input SNPs for the
EA and AA cohorts, respectively. Imputed SNPs that have an esti-
mated squared correlation between the estimated allele dosage and the
true allele dosage (dosage r2) , 0.3 were removed postanalysis. The
dosage r2 can be derived from arguments found in Appendix 1 of
Browning and Browning (2009). For this study, we supplemented
784,766 SNPs genotyped by the Illumina Omni1-Quad chip with
637,233 imputed SNPs with r2 . 0.3 for a total of 1,421,999 SNPs
in the ﬁnal genome-wide association report.
To assess the performance of imputation, analysis was performed
of a masked set of SNPs on chromosome 1. We ﬁrst masked
a randomly selected set of 20% of all Omni1 array SNPs on
chromosome 1 that passed the preimputation ﬁlters. The masked
SNPs were then removed from input ﬁles for imputation, and then
imputation was performed using the same procedures as described
previously. The imputed genotypes at the “masked” SNPs were then
compared with the experimental (typed) genotypes from Omni1
GWAS data to assess the accuracy of imputation. The SNP concor-
dance rates, which were deﬁned as fraction of identical genotypes
between the most likely imputed and observed, were 0.9858 for EA
and 0.9805 for AA (ﬁltering imputed genotypes at posterior probabil-
ity $ 0.9). The correlations between observed vs. expected allele fre-
quencies for all imputed SNPs were also very high (0.99967 for EA
and 0.99937 for AA). The plot of the observed allelic frequency vs.
expected allelic frequency from imputation is shown in supporting
information, Figure S1.
Statistical analysis
Summary statistics of study characteristics were calculated and
expressed as unadjusted means 6 SDs (SD) or percentages, stratiﬁed
by case status. We compared cases and controls for difference in
means using t-tests (for continuous variables) or difference in propor-
tions by x2 tests (for categorical variables) to obtain the unadjusted
two-sided P values. Logistic regression with case/control status as the
outcome and baseline characteristics as predictors was used to obtain
the age- and sex-adjusted P values. All summary statistics of study
characteristics were obtained using the STATA statistical package
(version 9.2; StataCorp, College Station, TX).
GWA analysis was performed using a logistic regression model to
test for associations of each SNP with IS under an additive model (for
imputed SNPs, estimated allelic dosage was used). A t-score was used
to assess the signiﬁcance of the beta coefﬁcient (b) for the SNP, and
the odds ratio (OR) was derived by exponentiation of the beta co-
efﬁcient. All estimates were obtained after adjusting for the effect of
age, recruitment periods (three indicator variables), and population
structure. Population structure was estimated using multidimensional
scaling (MDS) analysis on the matrix of genome-wide identical-by-
state (IBS) pairwise distances, which were estimated based on 127,901
typed (not imputed) SNPs that were selected for having MAF . 5%,
SNP call rates . 95%, and not being in linkage disequilibrium with
other selected SNPs (i.e. pair-wise LD between any two SNPs was
constrained to be r2 , 0.2). The ﬁrst 10 dimensions of population
structure were extracted using MDS, but only the ﬁrst dimension was
n Table 1 Subject exclusion criteria for genetic analysis in GEOS study
Exclusion Criteria
1. Known single-gene or mitochondrial disorders recognized by a distinctive phenotype; e.g., cerebral autosomal dominant arteriopathy with
subcortical infarcts and leukoencephalopathy (CADASIL), mitochondrial encephalopathy with lactic acidosis and stroke-like episodes
(MELAS), homocystinuria, Fabry disease, or sickle cell anemia
2. Mechanical aortic or mitral valve at the time of index stroke
3. Untreated or actively treated bacterial endocarditis at the time of the index stroke
4. Neurosyphilis or other CNS infections
5. Neurosarcoidosis
6. Severe sepsis with hypotension at the time of the index stroke
7. Cerebral vasculitis by angiogram and clinical criteria
8. Post-radiation arteriopathy
9. Left atrial myxoma
10. Major congenital heart disease
11. Cocaine use in the 48 hr prior to the index stroke
n Table 2 Population characteristics by case-control status
Characteristic
Case
(n = 889)
Control
(n= 927) Pa
Age (mean 6 SD, years) 41.3 6 6.9 39.6 6 6.8 ,0.001
Female (%) 41.5 43.6 0.37
Self-reported ethnicity (%)
White 52.42 56.42 0.22
African American 42.41 38.51
Other 5.17 5.07
Subtype (%)
Cardioembolic 20.0 ——
Large artery 7.1
Lacunar 16.1
Other known cause 6.5
Undetermined cause 50.3
Hypertension (%) 42.7 19.2 ,0.001
Diabetes mellitus (%) 16.7 5.1 ,0.001
Angina/myocardial infarction (%) 5.3 0.7 ,0.001
Current smoker (%) 42.5 28.6 ,0.001
a
Unadjusted P values for age, sex, and race; age and sex-adjusted P values for
other characteristics.
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the association analysis. Similar to imputation, study subjects were
divided into genetically deﬁned EA and AA groups for association
analyses based on population structure analysis. EA participants were
deﬁned as those failing within two SD of the mean of the ﬁrst and
second components for self-reported “white” subjects, and AA partic-
ipants were deﬁned as falling within two SD of the mean of the ﬁrst
and second components for self-reported “African American” sub-
jects. Association analyses were conducted in the total population,
adjusting for the ﬁrst MDS component, as well as for genetically de-
ﬁned EA and AA groups separately. Genome-wide signiﬁcance level
was set at a ¼ 5.0 · 1028 after Bonferroni correction for multiple
testing. All analyses were performed using existing programs imple-
mented in PLINK version 1.07 (Purcell et al. 2007). Power calculations
(using Quanto v1.2.4) indicated that our sample size of 889 cases and
927 controls provided 80% power to detect ORs ranging 1.55–2.30 for
allele frequencies ranging 10–50% at an a ¼ 5.0 · 1028.
We also reviewed previous genome-wide association studies on IS.
We identiﬁed one gene, NINJ2, reported previously to be genome-
wide signiﬁcantly associated with stroke risk in a large-scale meta-
analysis (CHARGE consortium) (Ikram et al. 2009). To replicate the
reported associations with NINJ2, a logistic regression model was
conducted under an additive genetic assumption to obtain beta coef-
ﬁcients (and odds ratios) and 95% conﬁdence intervals after adjusting
the same set of covariates described above. We ﬁrst tested whether the
two SNPs previously reported by CHARGE (rs12425791 and
rs11833579) were associated with young-onset stroke in our sample.
Because of our ap r i o r ihypothesis that each SNP would be associated
with young-onset IS, we did not adjust for multiple comparisons in
this analysis (a ¼ 0.05). We also conducted an agnostic screening of
all genotyped/imputed SNPs located within NINJ2 to identify the
most-signiﬁcant SNP from the gene based on empirical P values to
control for the number of SNPs tested. Empirical P values for the
most-signiﬁcant SNPs were obtained by permuting the case/control
status 1000 times to obtain the null distribution of the maximum T
statistics (over all SNPs within the gene) and calculating the number
of times the maximum test statistics exceeded the observed test sta-
tistic. Analyses were conducted using a set-based permutation pro-
cedure implemented in PLINK 1.07 (Purcell et al. 2007).
RESULTS
Characteristics of study population
A total of 1816 GEOS study participants, including 889 cases and 927
controls, were included in the analysis. Characteristics of study
participants are summarized in Table 2. The mean age was 41.3 years
for cases and 39.6 years for controls (P , 0.001). The population is
primarily composed of two self-reported race groups, white (54.5%)
and African American (40.4%), with the remaining 5.1% of individ-
uals comprising other races, including Chinese, Japanese, other
Asians, and other unspeciﬁed. There were more males than females
among both cases and controls. Cases were more likely than controls
to report having prevalent hypertension, diabetes, and myocardial
infarction and to being current smokers.
Genome-wide association of early-onset IS
Results from the GWA analysis are summarized in Figure 1. The
genomic inﬂation factor was 1.01, indicating that the distribution of
observed P values across most of the genome was consistent with that
expected under the null hypothesis. The 10 most strongly associated
SNPs are listed in Table 3. No single SNP reached genome-wide
signiﬁcance (a ¼ 5.0 · 1028). However, we found SNPs, rs2304556
(P ¼ 1.2 · 1027) and rs1986743 (P ¼ 2.7 · 1027) located on chro-
mosome 2q23.3, that were associated with IS but not at genome-wide
signiﬁcance (P , 5 · 1028). These two SNPs are separated by 113 kb
and are in strong linkage disequilibrium (LD) in EA (D9 ¼ 0.90, r2 ¼
0.75) although not in AA participants (D9 ¼ 0.35, r2 ¼ 0.08) in our
data [see Figure 2 for regional association plots for EA and AA
Figure 1 Negative log10 of genome-wide P values
from logistic regression model and a quantile-quantile
(Q-Q) plot (upper right) of the distribution of these ob-
served test statistics against expected distribution in
overall samples. Red dots represent the two most sig-
niﬁcant SNPs in chromosome 2q (rs2304556 and
rs1986743).
508 | Y-C. Cheng et al.obtained with the SNAP program (Johnson et al. 2008)]. The esti-
mated OR for both SNPs was 0.69 (95% CI = 0.60–0.79) per copy of
the minor allele (Table 3). The minor alleles of the two SNPs were
more common in controls than cases and more common in AA than
EA populations. The effects of the minor allele on risk of IS are similar
between EA and AA populations for rs2304556 (OR¼ 0.71, P ¼
0.00077 in EA and OR ¼ 0.71, P ¼ 0.0015 in AA, allele G) and for
rs1986743 (OR¼ 0.68, P ¼ 0.0002 in EA and OR ¼ 0.73, P ¼ 0.006 in
AA, allele A). After adjusting for the effect of rs2304556, the effect of
rs1986743 became nonsigniﬁcant in EA (OR ¼ 0.72, P ¼ 0.11) and
borderline signiﬁcant in AA (OR ¼ 0.79, P ¼ 0.06). Additionally, we
reexamined the associations of the two SNPs by further adjustment
for prior history of MI, hypertension, diabetes and for current smok-
ing, and the effects of the two SNPs remained similar (rs2304556:
OR ¼ 0.68, 95% CI ¼ 0.59 0.79; P ¼ 1.9 · 1027; rs1986743:
OR ¼ 0.70, 95% CI ¼ 0.61 0.82; P ¼ 3.6 · 1026). rs2304556 is in
the intron of FMNL2, which encodes a formin-related protein, and
rs1986743 is in the intron of ARL6IP6, which encodes ADP-ribosyla-
tion-like factor 6 interacting protein 6. The cluster plots of both SNPs
(rs2304556 and rs1986743) also showed clear separation of the three
genotypes, indicating good clustering of genotype calls for the two
SNPs (see Figure S2). Most of the other top-associated SNPs were
located in intergenic regions, except rs9465922 in an intron of
CDKAL1 and rs16834810 in an intron of RYR2.
No SNPs achieved genome-wide signiﬁcance in ethnic group–
speciﬁc analyses (data not shown). In the EA population, the SNP
most strongly associated with IS was rs2242878 at RUNX1 (OR ¼
1.81, 95% CI ¼ 1.42–2.31, P ¼ 1.8 · 1026, T allele), but this SNP was
not signiﬁcantly associated with IS in the AA population (OR ¼ 0.95,
95% CI ¼ 0.55–1.65, P ¼ 0.87). Similarly, the SNP most strongly
associated with IS in AAs was rs9604365 near SOX1 (OR ¼ 1.74,
95% CI ¼ 1.40–2.17, P ¼ 8.1 · 1027, allele G), but this SNP was
not associated with IS in EA (OR¼ 1.15, 95% CI ¼ 0.77–1.72, P ¼
0.5). It should be noted that rs9604365 was the tenth most signiﬁcant
SNP based on the overall population results (see Table 3).
Genome-wide association of stroke subtypes
We further analyzed the genome-wide associations stratiﬁed by each
stroke subtype deﬁned by TOAST criteria, including cardioembolic,
large artery, lacunar subtypes, other known causes, and other
undetermined causes. No SNPs were associated with any of the stroke
subtypes at genome-wide levels of statistical signiﬁcance, although the
power to detect associations for subtypes was very modest. Summary
results showing all SNPs associated with any stroke subtype at P ,
1.0 · 1025 in combined analyses of EA and AA are provided in Table
S1. Neither rs2304556 nor rs1986743, the two SNPs most strongly
associated with overall stroke in our sample, showed subtype-speciﬁc
patterns of association; i.e., the associations for both SNPs were ap-
proximately consistent across all stroke subtypes (ORs ranged 0.52–
0.76 for rs2304556 and 0.57–0.73 for rs1986743) (Table S2).
Replications of chromosome 2 SNP associations in other
Caucasian cohorts
There are currently no other large cohorts of young-onset stroke for
which to attempt replication. We did, however, assess the association
of rs2304556, our peak SNP, with IS in two independent Caucasian
cohorts with older-onset stroke: the Ischemic Stroke Genetics Study
and Siblings with Ischemic Stroke Studies (ISGS/SWISS; n ¼ 1070
cases and 1488 controls) and the Genes Affecting Stroke Risk and
Outcomes Study (GASROS; n ¼ 516 cases and 1202 controls). There
n
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Volume 1 November 2011 | GWAS of Early-Onset Ischemic Stroke | 509Figure 2 Regional association plots showing associations of FMNL2-ARL6IP6I region in European ancestry (top) and in African ancestry
populations (middle), and the position of the genes in this region (bottom). Each diamond represents a single typed SNP, and each square
represents a single imputed SNP. The color within each square/diamond represents the extent of LD correlation, r2, between the SNP and
510 | Y-C. Cheng et al.was no evidence for association with IS in either cohort (OR ¼ 1.10,
P ¼ 0.12 in ISGS/SWISS and OR ¼ 0.95, P ¼ 0.63 in GASROS
for minor allele G). These cohorts had 80% power to detect odds
ratios as low as 1.21 (ISGS/SWISS) and 1.26 (GASROS) for this SNP.
Associations of NINJ2 variants candidate genes with
early-onset IS
We additionally tested whether SNPs from NINJ2, which was identi-
ﬁed in a prior large GWAS study to be associated with IS, were
associated with young-onset stroke in our study (Table 4). Of the
two SNPs near NINJ2 that were previously reported to be associated
with IS (Ikram et al. 2009), neither was associated with early-onset IS
in our samples (rs11833579, combined P ¼ 0.54, EA P ¼ 0.99, AA
P ¼ 0.76; and rs12425791, combined P ¼ 0.49, EA P ¼ 0.74, AA P ¼
0.91). None of the other SNPs from NINJ2 was signiﬁcantly associated
with stroke risk in EA and AA populations after controlling for the
number of SNPs analyzed within the gene. When further investigating
the NINJ2 associations by TOAST subtypes, none of the SNPs was
signiﬁcantly associated with any of the stroke subtype, either (data not
shown).
DISCUSSION
Suggestive associations between chromosome 2q23.3
and early-onset IS
The GEOS Study is the largest genetics study of young-onset stroke
carried out to date. Despite having 80% power to detect odds ratios of
1.55–2.30 (at allele frequencies 10–50%), we had limited power
(,70%) to detect odds ratio less than 1.5 and failed to identify asso-
ciations with SNPs meeting conventional genome-wide levels of sig-
niﬁcance. However, we did detect associations with two SNPs on
chromosome 2q associated with overall IS that achieved nearly ge-
nome-wide levels of signiﬁcance (P , 2.65 · 1027). The most strongly
associated SNPs were near FMNL2 on chromosome 2. The minor
allele of this SNP (rs2304556), which is located in the intron of
FMNL2, is associated with an approximately 31% decrease in risk
per copy of minor allele in both EA and AA populations. A similar
association with stroke risk was observed for a nearby SNP,
rs1986743, located on ARL6IP6, although the strength of association
for this SNP diminished substantially after adjusting for rs2304556,
suggesting the two SNPs may not represent independent signals. As
there are no other large studies of young strokes currently available for
replication, we sought replication in two other cohorts with older
strokes (ISGS and GASROS). Although we were unable to replicate
the associations of the chromosome 2 SNPs in other Caucasian
cohorts, the lack of replications may be due to the genetic heteroge-
neity possibility between younger vs. older strokes.
FMNL2, which encodes formin-like 2 protein, is involved in actin-
dependent processes and is implicated in cell motility and invasion
(Kitzing et al. 2010). Although the function of this gene is largely un-
known, the gene is highly expressed in the brain and other central/
peripheral nervous system tissues (http://www.cgl.ucsf.edu/Research/
genentech/genehub-gepis/index.html) (Gardberg et al. 2010) and is
conserved in different species (http://www.ncbi.nlm.nih.gov/sites/
homologene). A microdeletion on chromosome 2q region involving
FMNL2 has previously been implicated in mental retardation
(Lybæk et al. 2009), and association and linkage studies have impli-
cated this same chromosomal region with susceptibility to autism
(Imgsac. 2001; Maestrini et al. 2009). The function of ARL6IP6 is
currently unknown. Replication studies, particularly in young stroke
cases, are required to assess the role of rs2304556 and/or other
variants in and around FMNL2 with young-onset stroke.
Interestingly, our GWAS also showed CDKAL1, a gene previously
shown to be associated with type 2 diabetes (T2D) (Scott et al. 2007;
Zeggini et al. 2007), to be marginally associated with IS in our data.
T2D is a strong risk factor for stroke. However, the association be-
tween rs9465922 and IS remained highly signiﬁcant after adjusting for
self-reported diabetes status in our population (OR ¼ 0.55, 95% ¼
0.44–0.70, P ¼ 5.5 · 1027), suggesting the effect of this gene on IS
may be independent of the effect of T2D. The function of CDKAL1 is
not currently known, although the association of this gene to T2D
may be related to an effect of the associated SNP on insulin response
(Steinthorsdottir et al. 2007).
Failure to replicate previously reported associations
with NINJ2
We were unable to replicate the previous GWA associations with two
SNPs in NINJ2 as reported by the CHARGE consortium (Ikram et al.
2009), even though power was 98% in our sample to detect associa-
tions of the magnitude of that observed in CHARGE (OR = 1.39–1.41
rs2304556. The blue line represents the recombination rate. Recombination rate and r2 were estimated based on HapMap3 CEU and YRI samples,
respectively. Regional association plots were drawn by modifying the R program codes from the SNAP program, and the position of the gene
were obtained from the University of California, Santa Cruz (UCSC) genome browser.
n Table 4 Association results of NINJ2 in the GEOS Study
Previously Reported Variant Best SNP within the Gene
No. of SNPsa Variant
Effect/Noneffect
Allele OR (95% CI) Pb Variant
Effect/Noneffect
Allele OR (95% CI) Pb Empirical Pc
EAd 70 rs12425791 A/G 0.96 (0.76, 1.21) 0.74 rs12229103 A/C 1.34 (0.90, 2.00) 0.15 0.95
rs11833579 A/G 1.00 (0.81, 1.24) 0.99
AAd 70 rs12425791 A/G 1.02 (0.73, 1.42) 0.91 rs11063749 T/C 0.74 (0.60, 0.93) 0.008 0.27
rs11833579 A/G 1.04 (0.80, 1.35) 0.76
Abbreviations: CI, conﬁdence interval; OR, odds ratio; P, association P value.
a
Number of SNPs within the gene that were either directly genotyped (SNP call rate . 95% and HWE P . 1.0 · 1027 in either European or African ancestry) or
imputed (imputation dosage r2 . 0.3).
b
Nominal P was obtained by t-statistics in the logistic regression.
c
Empirical P was obtained by permutations as described in Materials and Methods.
d
European ancestry (EA) and African ancestry (AA) are deﬁned based on multidimensional scaling (MDS) analysis.
Volume 1 November 2011 | GWAS of Early-Onset Ischemic Stroke | 511for SNPs with these allele frequencies). Notably, the association with
NINJ2 reported in CHARGE could also not be replicated in a recent
very large meta-analysis by the International Stroke Genetics Consor-
tium and Wellcome Trust Case-Control Consortium 2 (2010).
Strengths and limitations of the study
We used the strategy of studying the early-onset form of IS to identify
genetic variants associated with this complex disease because the
early-onset form may be less susceptible to the inﬂuence of
environmental exposures, and genetic components could potentially
have a greater contribution to disease risk. Although it is possible that
genetic variants associated with early-onset stroke may have little
relevance to late-onset stroke, it is also possible that studying early-
onset form of diseases may reveal important insights about stroke
pathogenesis, even implicating key genes and pathways relevant to
late-onset disease even though the responsible variants may differ.
Although we did identify a region on chromosome 2 with
suggestive evidence for association in the GEOS population, we did
not identify any variants reaching conventional thresholds for
statistical signiﬁcance at a genome-wide level. The absence of robust
associations may be due to the limited sample size that provided
insufﬁcient power to detect causal variants with small effect sizes (e.g.
less than 80% power to detect genetic risk effect less than 1.55).
Alternatively, one can argue that the early-onset form of IS may be
more likely to be caused by rare variants with larger effects (and
higher penetrance). Such rare variants are generally not well covered
on currently available genotyping platforms and, thus, would be difﬁ-
cult to detect through a GWA approach. Exome and/or whole-genome
sequencing may be a promising research approach to pursue the
roles of these infrequent and highly penetrant variants on IS risk.
Notably, our ability to identify IS-associated variants could be further
limited by the stroke phenotype itself, which is composed of several
heterogeneous subtypes with different underlying causes and poten-
tially different genetic dispositions (Marnane et al. 2010). Thus, the
genetic variants contributing to stroke risk may differ based upon
stroke subtype. Although we analyzed according to TOAST subtype,
in doing so we incurred further losses in power due to the smaller
number of cases available in each subtype. As IS occurs infrequently
before age 50, it is difﬁcult for a single study to obtain the sufﬁcient
number of strokes necessary to power subtype-speciﬁc analyses.
Therefore, combining genetic data among multiple early-onset stroke
studies to increase the number of cases for overall stroke and stroke
subtype analyses will be essential to ensure sufﬁcient power to detect
causal variants with moderate effects.
Conclusions
Our early-onset IS GWA study identiﬁed a novel IS susceptibility
region around FMNL2 on chromosome 2q. Further studies in other
young-stroke populations are needed to replicate these ﬁndings and to
evaluate the associations between these SNPs and the more common
older-onset form of stroke. Meta-analysis of early-onset stroke ensur-
ing sufﬁcient statistical power for moderate genetic effects and se-
quencing efforts to explore the effect of rare variants are also required.
ACKNOWLEDGMENTS
GEOS was supported by the National Institutes of Health (NIH) Genes,
Environment and Health Initiative (GEI) Grant U01 HG-004436, as
part of the GENEVA consortium under GEI, with additional support
provided by the Mid-Atlantic Nutrition and Obesity Research Center
(P30 DK-072488); and by the Ofﬁce of Research and Development,
Medical Research Service, and the Baltimore Geriatrics Research,
Education, and Clinical Center of the Department of Veterans
Affairs. Genotyping services were provided by the Johns Hopkins
University Center for Inherited Disease Research (CIDR) and
funded by GEI Grant U01 HG-004438-01. Assistance with data
cleaning was provided by the GENEVA Coordinating Center (U01
HG-004446; Bruce S. Weir, P.I.). Study recruitment and assembly of
datasets were supported by a Cooperative Agreement with the
Division of Adult and Community Health, Centers for Disease
Control, and by National Institute of Neurological Disorders and
Stroke (NINDS) and NIH Ofﬁce of Research on Women's Health
Grants R01 NS-45012 and U01 NS-069208-01. The ISGS/SWISS
study was supported in part by the Intramural Research Program
of the National Institute on Aging, NIH project Z01 AG-000954-06.
ISGS/SWISS used samples and clinical data from the NIH-NINDS
Human Genetics Resource Center DNA and Cell Line Repository
(http://ccr.coriell.org/ninds), human subjects protocol numbers
2003-081 and 2004-147. ISGS/SWISS used stroke-free participants
from the Baltimore Longitudinal Study of Aging (BLSA) as controls.
The inclusion of BLSA samples was supported in part by the Intra-
mural Research Program of the National Institute on Aging, NIH
project Z01 AG-000015-50, human subjects protocol number 2003-
078.The ISGS study was funded by NIH-NINDS Grant R01 NS-42733
(J. F. Meschia, P.I.). The SWISS study was funded by NIH-NINDS
Grant R01 NS-39987 (J. F. Meschia, P.I.). This study utilized the
high-performance computational capabilities of the Biowulf Linux
cluster at the NIH (http://biowulf.nih.gov). GASROS was supported
by American Heart Association/Bugher Foundation Centers for
Stroke Prevention Research Grant 0775010N; NIH-NINDS Grants
K23 NS-064052 (N. S. Rost), R01 NS-063925 (J. Rosand), and P50
NS-051343 (J. Rosand and K. L. Furie); the Deane Institute for In-
tegrative Study of Atrial Fibrillation and Stroke; and the Keane
Stroke Genetics Research Fund. Drs. A. Bifﬁ, N. S. Rost, and C. D.
Anderson were supported in part by the American Heart Associa-
tion/Bugher Foundation Centers for Stroke Prevention Research.
LITERATURE CITED
Adams, H. P. Jr, B. H. Bendixen, L. J. Kappelle, J. Biller, B. B. Love et al.,
1993 Classiﬁcation of subtype of acute ischemic stroke. Deﬁnitions for
use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute
Stroke Treatment. Stroke 24: 35–41.
Brass, L. M., J. L. Isaacsohn, K. R. Merikangas, and C. D. Robinette, 1992 A
study of twins and stroke. Stroke 23: 221–223.
Brass, L. M., W. F. Page, and J. H. Lichtman, 1998 Stroke in twins III:
a follow-up study. Stroke 29(Suppl): 256.
Browning, B. L., and S. R. Browning, 2009 A uniﬁed approach to genotype
imputation and haplotype-phase inference for large data sets of trios and
unrelated individuals. Am. J. Hum. Genet. 84: 210–223.
Flossmann, E., U. G. Schulz, and P. M. Rothwell, 2004 Systematic review of
methods and results of studies of the genetic epidemiology of ischemic
stroke. Stroke 35: 212–227.
Gardberg, M., K. Talvinen, K. Kaipio, K. Iljin, C. Kampf et al.,
2010 Characterization of Diaphanous-related formin FMNL2 in human
tissues. BMC Cell Biol. 11: 55.
Hao, K., E. Chudin, J. McElwee, and E. Schadt, 2009 Accuracy of genome-
wide imputation of untyped markers and impacts on statistical power for
association studies. BMC Genet. 10: 27.
Hassan, A., and H. S. Markus, 2000 Genetics and ischaemic stroke. Brain
123(Pt 9): 1784–1812.
Hinney, A., T. T. Nguyen, A. Scherag, S. Friedel, G. Bronner et al.,
2007 Genome wide association (GWA) study for early onset extreme
obesity supports the role of fat mass and obesity associated gene (FTO)
variants. PLoS ONE 2: e1361.
512 | Y-C. Cheng et al.Ikram, M. A., S. Seshadri, J. C. Bis, M. Fornage, A. L. DeStefano et al.,
2009 Genomewide association studies of stroke. N. Engl. J. Med. 360:
1718–1728.
Imielinski, M., R. N. Baldassano, A. Grifﬁths, R. K. Russell, V. Annese et al.,
2009 Common variants at ﬁve new loci associated with early-onset
inﬂammatory bowel disease. Nat. Genet. 41: 1335–1340.
International Molecular Genetic Study of Autism Consortium (IMGSAC),
2001 A genomewide screen for autism: strong evidence for linkage to
chromosomes 2q, 7q, and 16p. Am. J. Hum. Genet. 69: 570–581.
International Stroke Genetics Consortium and Wellcome Trust Case-Control
Consortium 2, 2010 Failure to validate association between 12p13
variants and ischemic stroke. N. Engl. J. Med. 362: 1547–1550.
Johnson, A. D., R. E. Handsaker, S. L. Pulit, M. M. Nizzari, C. J. O’Donnell
et al., 2008 SNAP: a web-based tool for identiﬁcation and annotation of
proxy SNPs using HapMap. Bioinformatics 24: 2938–2939.
Johnson, C. J., S. J. Kittner, R. J. McCarter, M. A. Sloan, B. J. Stern et al.,
1995 Interrater reliability of an etiologic classiﬁcation of ischemic
stroke. Stroke 26: 46–51.
Kathiresan, S., B. F. Voight, S. Purcell, K. Musunuru, D. Ardissino et al.,
2009 Genome-wide association of early-onset myocardial infarction
with single nucleotide polymorphisms and copy number variants. Nat.
Genet. 41: 334–341.
Kittner, S. J., B. J. Stern, M. Wozniak, D. W. Buchholz, C. J. Earley et al.,
1998 Cerebral infarction in young adults: the Baltimore-Washington
Cooperative Young Stroke Study. Neurology 50: 890–894.
Kitzing, T. M., Y. Wang, O. Pertz, J. W. Copeland, and R. Grosse,
2010 Formin-like 2 drives amoeboid invasive cell motility downstream
of RhoC. Oncogene 29: 2441–2448.
Lesage, S., E. Lohmann, F. Tison, F. Durif, A. Durr et al., 2008 Rare het-
erozygous parkin variants in French early-onset Parkinson disease pa-
tients and controls. J. Med. Genet. 45: 43–46.
L y b æ k ,H . ,K .H .Ø r s t a v i k ,T .P r e s c o t t ,R .H o v l a n d ,H .B r e i l i d ,et al.,
2009 An 8.9 Mb 19p13 duplication associated with precocious pu-
berty and a sporadic 3.9 Mb 2q23.3q24.1 deletion containing NR4A2
in mentally retarded members of a family with an intrachromosomal
19p-into-19q between-arm insertion. Eur. J. Hum. Genet. 17: 904–
910.
MacClellan, L. R., B. D. Mitchell, J. W. Cole, M. A. Wozniak, B. J. Stern et al.,
2006 Familial aggregation of ischemic stroke in young women: the
Stroke Prevention in Young Women Study. Genet. Epidemiol. 30: 602–
608.
Maestrini, E., A. T. Pagnamenta, J. A. Lamb, E. Bacchelli, N. H. Sykes et al.,
2009 High-density SNP association study and copy number variation
analysis of the AUTS1 and AUTS5 loci implicate the IMMP2L-DOCK4
gene region in autism susceptibility. Mol. Psychiatry. 15: 954–968.
Marnane, M., C. A. Duggan, O. C. Sheehan, A. Merwick, N. Hannon et al.,
2010 Stroke subtype classiﬁcation to mechanism-speciﬁc and undeter-
mined categories by TOAST, A-S-C-O, and causative classiﬁcation sys-
tem: direct comparison in the North Dublin Population Stroke Study.
Stroke 41: 1579–1586.
Purcell, S., B. Neale, K. Todd-Brown, L. Thomas, M. A. Ferreira et al.,
2007 PLINK: a tool set for whole-genome association and population-
based linkage analyses. Am. J. Hum. Genet. 81: 559–575.
Rosamond, W., K. Flegal, K. Furie, A. Go, K. Greenlund et al., 2008 Heart
disease and stroke statistics–2008 update: a report from the American
Heart Association Statistics Committee and Stroke Statistics Subcom-
mittee. Circulation 117: e25–e146.
Scherag, A., C. Dina, A. Hinney, V. Vatin, S. Scherag et al., 2010 Two new
loci for body-weight regulation identiﬁed in a joint analysis of genome-
wide association studies for early-onset extreme obesity in French and
German study groups. PLoS Genet. 6: e1000916.
Schulz, U. G., E. Flossmann, and P. M. Rothwell, 2004 Heritability of is-
chemic stroke in relation to age, vascular risk factors, and subtypes of
incident stroke in population-based studies. Stroke 35: 819–824.
Scott, L. J., K. L. Mohlke, L. L. Bonnycastle, C. J. Willer, Y. Li et al., 2007 A
genome-wide association study of type 2 diabetes in Finns detects mul-
tiple susceptibility variants. Science 316: 1341–1345.
Steinthorsdottir, V., G. Thorleifsson, I. Reynisdottir, R. Benediktsson, T.
Jonsdottir et al., 2007 A variant in CDKAL1 inﬂuences insulin response
and risk of type 2 diabetes. Nat. Genet. 39: 770–775.
Walsh, T., S. Casadei, K. H. Coats, E. Swisher, S. M. Stray et al.,
2006 Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in
families at high risk of breast cancer. JAMA 295: 1379–1388.
Zeggini, E., M. N. Weedon, C. M. Lindgren, T. M. Frayling, K. S. Elliott et al.,
2007 Replication of genome-wide association signals in UK samples
reveals risk loci for type 2 diabetes. Science 316: 1336–1341.
Communicating editor: S. W. Scherer
Volume 1 November 2011 | GWAS of Early-Onset Ischemic Stroke | 513